---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-205350"
form_type: "8-K"
ticker: "FBRX"
cik: "0001419041"
company_name: "Forte Biosciences, Inc."
filed_at: "2024-08-22T23:59:59+00:00"
generated_at: "2026-05-31T08:02:40.894121+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Forte Biosciences secures shareholder approval for 1-for-25 reverse split effective Aug 28

## Summary
- Reverse stock split ratio set at 1-for-25; effective Aug 28, 2024, with new CUSIP 34962G 208.
- Stockholders approved amendment to effect reverse split (26.7M for, 2.1M against).
- Amended 2021 Equity Incentive Plan approved (17.3M for, 6.9M against); adds up to 8.5M new shares plus up to 1.1M from prior plans.
- Class I directors elected: Barbara K. Finck, M.D. (18.8M for), Donald A. Williams (15.4M for), Stephen K. Doberstein (15.1M for).
- KPMG LLP ratified as independent auditor for FY2024 with 28.8M votes for.

## SEC filing metadata
- accession: 0001193125-24-205350
- form_type: 8-K
- ticker: FBRX
- cik: 0001419041
- company_name: Forte Biosciences, Inc.
- filed_at: 2024-08-22T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 5.07, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1419041/000119312524205350/0001193125-24-205350-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1419041/000119312524205350/d888554d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-205350
- JSON: https://secwatch.observer/filing/0001193125-24-205350.json
- Plain text: https://secwatch.observer/filing/0001193125-24-205350.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.